Pediatrician (St. Petersburg)Pediatrician (St. Petersburg)2079-78502587-6252Eco-Vector1916410.17816/PED10593-99Research ArticlePituitary gigantism. The possibility of medical treatmentTyrtovaLjudmila V.<p>MD, PhD, Dr Med Sci, Professor Department of Faculty Pediatrics, Head of the Endocrinology Department of the Clinic</p>dr-tyrtova@yandex.ruOlenevAleksej S.<p>MD, PhD, Associate Professor, Department of Faculty Pediatrics, doctor of the Endocrinology Department of the Clinic</p>A.S.Olenev@gmail.comParshinaNatalja V.<p>MD, PhD, Associate Professor, Department of Faculty Pediatrics</p>dr-parshinanv@yandex.ruSkobelevaChristina V.<p>Doctor of the Endocrinology Department of the Clinic</p>skobeleva_kv@mail.ruSt. Petersburg State Pediatric Medical University, Ministry of Healthcare of the Russian Federation2812201910593992801202028012020Copyright © 2020, Tyrtova L.V., Olenev A.S., Parshina N.V., Skobeleva C.V.2020<p>Pituitary gigantism is a disease caused by an excess of growth hormone and characterized by tallness with a proportional increase in all parts of the body. Almost always in patients with pituitary gigantism found pituitary adenoma, producing growth hormone (somatotropin). In rare cases, there is excess production of somatoliberin by the hypothalamus or tumors outside the brain. Somatotropinoma can be sporadic or caused by a disease with genetic defects: multiple endocrine neoplasia type 1, McCuneAlbright syndrome, Carney complex, X-LAG syndrome, AIP-mutation. All associated with genetic defects somatotropinoma more invasive and less amenable to drug therapy than sporadic. Clinical recommendations (protocols) for the treatment of pituitary gigantism in children currently does not exist. The issue of preliminary medical treatment to improve the outcome of neurosurgical interventions has not been resolved, and further methodologically based studies are needed to clarify this point. The article presents a clinical case of pituitarygigantism caused by pituitary adenoma, which produces growth hormone in a 12-year-old boy. The diagnosis was established on the basis of clinical and anamnestic, laboratory data and magnetic resonance imaging. Clinical and laboratory manifestations of hypopituitarism and diabetes insipidus, visual field disorders, neurological symptoms, as well as signs of genetic diseases in the patient were not noted. Treatment with bromocriptin gave a partial positive effect: the size of the formation in the pituitary gland decreased, but the target hormonal parameters were not achieved. A trial administration of octreotide subcutaneously was carried out, as a result of which the level of growth hormone decreased to the target values, no side effects of the drug were noted, which led to the choice of a conservative method as the first line of therapy. Thedecision to treat with bromocryptine in combination with octreotide extended action. The dynamics of tumor sizeonthebackgroundofconservative therapy will answer the question of the need for subsequent neurosurgical treatment.</p>pituitary gigantismchildrensomatotropinomadrug therapyoctreotideгипофизарный гигантизмдетисоматотропиномамедикаментозная терапияоктреотид[Иловайская И.А. Выявление и преодоление резистентности к аналогам соматостатина в реальной клинической практике // Проблемы эндокринологии. – 2017. – Т. 63. – № 5. – С. 338–345. [Ilovayskaya IA. Identification and overcoming of resistance to somatostatin analogues in real clinical practice. Problems of endocrinology. 2017;63(5):338-345. (In Russ.)] https://doi.org/10.14341/probl2017635338-345.][Кадашев Б.А., Коновалов А.Н., Астафьева Л.И., и др. Эндокринные расстройства до и после операции при различных поражениях стебля гипофиза супраселлярно растущими опухолями // Вопросы нейрохирургии им. Н.Н. Бурденко. – 2018. – Т. 82. – № 1. – С. 13–21. [Kadashev BA, Konovalov AN, Astaf’eva LI, et al. Preoperative and postoperative endocrine disorders associated with pituitary stalk injuries caused by suprasellary growing tumors. Zh Vopr Neirokhir Im N N Burdenko. 2018;82(1):13-21. (In Russ.)]. https://doi.org/10.17116/neiro201882113-21.][Лисс В.Л., Скородок Ю.Л., Плотникова Е.В., и др. Диагностика и лечение эндокринных заболеваний у детей и подростков. – СПб.: МЕДпресс-информ, 2017. [Liss VL, Skorodok YL, Plotnikova EV, et al. Diagnostika i lechenie endokrinnykh zabolevaniy u detey i podrostkov. Saint Petersburg: MEDpress-inform; 2017. (In Russ.)][Пронин В.С., Чуброва Н.А., Жеребчикова К.Ю., и др. Проблемы и перспективы медикаментозного лечения акромегалии // Доктор.Ру. – 2014. – № 12. – С. 56–61. [Pronin VS, Tchubrova NA, Zherebchikova KYu, et al. Medications for Acromegaly: Challenges and Perspectives. Doctor.Ru. 2014;(12):56-61. (In Russ.)]][Радулеску Г.Г., Матченкова Н.В., Белогурова М.Б. Эндокринологические осложнения у пациентов, получивших противоопухолевую терапию в детском возрасте // Педиатр. – 2016. – Т. 7. – № 1. – С. 120–128. [Radulesku GG, Matchenkova NV, Belogurova МB. The endocrinologic complications in children after anticancer treatment. Pediatrician (St. Petersburg). 2016;7(1):120-128. (In Russ.)] https://doi.org/10.17816/PED71120-128.][Beckers A, Aaltonen LA, Daly AF, Karhu A. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev. 2013;34(2):239-277. https://doi.org/10.1210/er.2012-1013.][Beckers A, Rostomyan L, Potorac I, et al. X-LAG: How did they grow so tall? Ann Endocrinol (Paris). 2017;78(2):131-136. https://doi.org/10.1016/j.ando.2017.04.013.][Burton T, Le Nestour E, Neary M, Ludlam WH. Incidence and prevalence of acromegaly in a large US health plan database. Pituitary. 2016;19(3):262-267. https://doi.org/10.1007/s11102-015-0701-2][Cecenarro LA, Rodrigo Fanton ET, et al. Pituitary tumors: 10 years of experience. Rev Fac Cien Med Univ Nac Cordoba. 2015;72(1):32-38.][de Herder WW. The History of Acromegaly. Neuroendocrinology. 2016;103(1):7-17. https://doi.org/10.1159/ 000371808.][Gadelha MR, Kasuki L, Korbonits M. The genetic background of acromegaly. Pituitary. 2017;20(1):10-21. https://doi.org/10.1007/s11102-017-0789-7.][Joshi K, Daly AF, Beckers A, Zacharin M. Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant. Horm Res Paediatr. 2018;90(3): 196-202. https://doi.org/10.1159/000488856.][Katznelson L, Laws ER, Jr., Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(11):3933-3951. https://doi.org/10.1210/jc.2014-2700.][Kuhn E, Chanson P. Cabergoline in acromegaly. Pituitary. 2017;20(1):121-128. https://doi.org/10.1007/s11102-016-0782-6.][Losa M, Bollerslev J. Pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly. Endocrine. 2016;52(3):451-457. https://doi.org/10.1007/s12020-015-0853-x.][Marazuela M, Ramos-Leví A, Sampedro-Núñez M, Bernabeu I. Cabergoline treatment in acromegaly: pros. Endocrine. 2014;46(2):215-219. https://doi.org/ 10.1007/s12020-014-0206-1.][Nozieres C, Berlier P, Dupuis C, et al. Sporadic and genetic forms of paediatric somatotropinoma: a retrospective analysis of seven cases and a review of the literature. Orphanet J Rare Dis. 2011;6:67. https://doi.org/10.1186/1750-1172-6-67.][Saldarriaga C, Lyssikatos C, Belyavskaya E, et al. Postoperative Diabetes Insipidus and Hyponatremia in Children after Transsphenoidal Surgery for Adrenocorticotropin Hormone and Growth Hormone Secreting Adenomas. J Pediatr. 2018;195:169-174 e161. https://doi.org/10.1016/j.jpeds.2017.11.042.][Salenave S, Boyce AM, Collins MT, Chanson P. Acromegaly and McCune-Albright syndrome. J Clin Endocrinol Metab. 2014;99(6):1955-1969. https://doi.org/10.1210/jc.2013-3826.][Salpea P, Stratakis CA. Carney complex and McCune Albright syndrome: an overview of clinical manifestations and human molecular genetics. Mol Cell Endocrinol. 2014;386(1-2):85-91. https://doi.org/10.1016/j.mce.2013.08.022.][Feng SY, Zhou T, Sun ZH, et al. Anterior interhemispheric approach for removing large sellar region tumor. Medicine (Baltimore). 2018;97(24): e10840. https://doi.org/10.1097/MD.0000000000010840.][Tichomirowa MA, Barlier A, Daly AF, et al. High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol. 2011;165(4): 509-515. https://doi.org/10.1530/EJE-11-0304.]